Skip to content

Pharma

Soft CL slows myopia in children

Soft CL slows myopia in children

Globally, the myopia market may be worth upwards of $28 billion by 2026, with single prescription corrective lenses holding a significant market share, according to one report. CooperVision’s first contact lens indicated to slow the progression of myopia in children was approved in mid-November and may garner an impressive part of that market share —…

Read More

Lucentis and Eylea patent expirations in the micro-crystal ball

Lucentis and Eylea patent expirations in the micro-crystal ball

Over the past 10 years, the Dow Jones Industrial Average has seen a 10-year climb with small calendar-year dips seen in 2015 (-2.23%) and 2018 (-5.63%), but topping out at around 28,000 toward the end of 2019. Investors can only wonder: How long can that bull market last? This year is a U.S. presidential election.…

Read More

Innovations a Highlight at Dry Eye Breakout Session

Innovations a Highlight at Dry Eye Breakout Session

The dry eye disease (DED) market is expected to have an annual compound growth rate of 4.5% between 2017 and 2025, which should help it reach $7.7 billion by 2025. The North American market valuation by 2025 is expected to be close to $3 billion. Needless to say, at the recent OIS@AAO, the Dry Eye…

Read More

BioGenware’s Speculet Seeks to Improve the Patient Experience

BioGenware’s Speculet Seeks to Improve the Patient Experience

For those undergoing intravitreal injections (and there are about 22 million of these performed yearly worldwide), a common complaint is that the speculum is uncomfortable, sometimes even downright painful. Jeffrey Gross, MD, co-founder & managing partner, BioGenware, and founder & president of the Carolina Retina Center, developed a device along with co-founder and partner John…

Read More

We’ve Got Your BAK

We’ve Got Your BAK

Imagine a world where you could use as much preservative as you needed in a prescription eye drop without ever having to worry it would reach the cornea? Well, that’s exactly what TearClear is doing in an attempt to get a slice of the $3.7 billion glaucoma medication market. TearClear aims to be the premier…

Read More

CorneaGen Aims to End Corneal Blindness

CorneaGen Aims to End Corneal Blindness

CorneaGen’s approach to treating corneal blindness is to prevent it from ever occurring, said Monty Montoya, president and CEO, who added no other organization has studied the whole cornea ecosystem quite as intricately as CorneaGen. Wall Street seems to agree — the company recently completed $37 million in Series B funding, led by Flying L…

Read More

RegenxBio sues FDA over clinical hold

RegenxBio sues FDA over clinical hold

Days after the U.S. Food and Drug Administration placed a partial hold on RGX-314, RegenxBio (NASDAQ: RGNX) lead gene therapy agent, the company initially outlined common responses (delaying an investigational new drug [IND], continued assessment and monitoring, etc.), but then did something completely unexpected — it sued the FDA, seeking to set the hold aside,…

Read More

Bausch, Clearside See Gains Post-Deal

Bausch, Clearside See Gains Post-Deal

When it comes to the stock market, Bausch Health’s has been rising steadily, up 4.1% in the past month, and on November 13 hit a 52-week high; Zacks Equity Research thinks the recent run may continue, and with good reason as the company just partnered with Clearside Biomedical to enter into the suprachoroidal space with…

Read More

Oyster Point Pharma Goes Public

OIS INDEX Oyster Point

Oyster Point Pharma is now officially listed on the Nasdaq Global Market under “OYST.” Initial share pricing was $16; to date the stock’s high has been $19.01, while its low has been $15.16. Look for Oyster Point to join the OIS Index in the next report. Oyster Point Pharma’s lead product candidate, OC-01, a highly…

Read More

Digging deep in the retina pipeline

Digging deep in the retina pipeline

While Novartis’ recently approved Beovu soaked up a lot of the buzz in the retina space at the American Academy of Ophthalmology, reports of early phase research at OIS@AAO may provide a glimpse of what will be the buzz five or 10 years from now, if not sooner. They include a fully degradable implant to…

Read More

Ain’t Misbehaving

Ain’t Misbehaving

What a difference a day (or so) makes. On Oct. 10, the day of the Ophthalmic Innovation Summit, Aerie Pharmaceuticals’ stock closed at $17.72. The next day, it closed at $20.15. On Oct. 21, the day’s high was $20.70; it closed at $19.59. Is this any way for Aerie’s stock to behave? The company launched…

Read More
Scroll To Top